enGene Inc. Appoints Dr. Richard M. Glickman to the Company's Board of Directors and Announces Changes to Its Board Composition
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 10/21/11 -- enGene Inc., a privately held biotechnology company headquartered in Vancouver, announced today the appointment of Dr. Richard M. Glickman, a successful biotech entrepreneur and highly experienced healthcare professional to its Board of Directors.
Dr. Richard Glickman was a co-founder and Chief Executive Officer of Aspreva Pharmaceuticals. Under his leadership, Aspreva grew into a highly profitable public company. Aspreva was acquired for nearly $1Bln in October 2007. Prior to Aspreva, Richard was the co-founder and Chief Executive Officer of StressGen Biotechnologies Corporation, where he grew the company from startup to a major biotechnology player with a market capitalization of over $500 million. He was also the founder and a director of Ontario Molecular Diagnostics, which evolved into the largest molecular diagnostic laboratories in Canada. Richard also co-founded Probtec Corporation, a rational drug design and molecular genetics firm, where he established and introduced the first licensed DNA-based forensic and paternity testing services in Canada. He has served on numerous biotechnology boards including roles as Chairman of Life Sciences B.C., Director of the Canadian Genetic Disease Network and a member of the federal government's National Biotechnology Advisory Committee. Richard received the Ernst & Young Entrepreneur of the Year Award in 2004; both Canada's and British Columbia's Top 40 under 40 Award for Entrepreneurs; and the BC Biotech Leadership Award in 2006. Richard currently serves as a director for a number of private and public biotechnology companies.
"The addition of Dr. Glickman to our Board will bring tremendous benefit to enGene, as we seek financing to advance our technology into human clinical trials," said Dr. Anthony Cheung, co-founder and Interim CEO. "Richard brings to enGene a wealth of experience in drug development, strong track record in building successful biotech enterprises and many connections to relevant investor groups. Furthermore, the Company welcomes his strategic guidance to Management and the Board, as we focus on advancing enGene through its next phase of growth."
In addition, Dr. Anthony Cheung has been added to the Board. This reorganization of the Board was made possible by the voluntary retirement of two existing Board members, Hector McKay-Dunn, Q.C. and Sinclair Dunlop. Mr Dunlop will remain an Observer to the Board. "On behalf of all stakeholders in enGene, I would like to express our sincere appreciation to Hector and Sinclair for their tireless contributions and dedication to enGene in the past 6 and 4 years, respectively," said Mr. Francis Gargiulo, an investor and a founding Director of enGene. "Their knowledge and leadership helped our Company tremendously in steering through many critical challenges we faced in these past years. With the new Board members, we are well positioned to build upon initiatives that have begun in the recent years to further enhance the value of enGene."
More about enGene
enGene Inc. has developed a highly flexible, biopolymer-based nucleotide (DNA and siRNA) delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels. Our platform technology has the ability to significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lung and bladder as well as provide systemic release of proteins from the gut to treat diabetes, anemia, hemophilia and others. The two lead programs are the localized delivery of an anti-inflammatory cytokine, IL-10, for treating Inflammatory Bowel Disease and delivery of insulin in a physiologic, meal-dependent fashion to regulate blood glucose levels. For more information please visit .
Contacts:
enGene Inc.
Anthony T. Cheung
Interim CEO
604.221.4362
604.221.4369 (FAX)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.10.2011 - 17:17 Uhr
Sprache: Deutsch
News-ID 1048700
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
VANCOUVER, BRITISH COLUMBIA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 104 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"enGene Inc. Appoints Dr. Richard M. Glickman to the Company's Board of Directors and Announces Changes to Its Board Composition
"
steht unter der journalistisch-redaktionellen Verantwortung von
enGene Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
